COVID-19 treatment information | Alaska Native Tribal Health Consortium

COVID-19 treatment information

Patients today have multiple treatment options if they test positive for COVID-19. The U.S. Food and Drug Administration (FDA) has approved one drug treatment for COVID-19 and has authorized others for emergency use during this public health emergency. In addition, many more therapies are being tested in clinical trials to evaluate whether they are safe and effective in combating COVID-19.

Here is some additional information about available COVID-19 treatments that have been deemed safe and appropriate for use at this time. Studies are ongoing and patients should talk to their health care provider about available treatment options if you have COVID-19. Your provider will know the best option for you, based on your symptoms, risks and health history. Additional information on treatments can be found at


The FDA has approved the antiviral drug Veklury (remdesivir) for adults and certain pediatric patients with COVID-19 who are sick enough to need hospitalization. Remdesivir is used for the treatment of patients admitted with severe COVID-19 pneumonia and can be considered in patients admitted to the hospital due to moderate COVID-19. It has been shown to shorten time to recovery and duration of symptoms.

Remdesivir is FDA approved for adults aged 18 and older.

Monoclonal Antibodies

Patients 12 and older who recently tested positive for COVID-19 may be eligible for monoclonal antibody treatment. This can help prevent severe illness and hospitalization.

You can speak health care provider or call the statewide Alaska COVID helpline at (907) 646-3322 for more information.

Monoclonal antibodies support your body’s own antibodies and help your immune system destroy the virus that causes COVID-19 more quickly, often before it causes hospitalization. The U.S. Food and Drug Administration has authorized monoclonal antibody treatment for emergency use for eligible patients, regardless of vaccination status.

Factors that may increase your risk for severe COVID-19 illness:

  • Not being fully vaccinated (i.e. at least two weeks after your second dose of Pfizer/Moderna or single dose of Johnson & Johnson vaccine)
  • Older age (≥65 years of age)
  • Obesity or being overweight (for example, BMI >25 kg/m2, or if age 12-17, have BMI ≥85th percentile for their age and gender based on CDC growth charts)
  • Pregnancy
  • Chronic kidney disease
  • Diabetes
  • Having a weakened immune system from health conditions or medications
  • Heart disease
  • High blood pressure
  • Chronic lung diseases (for example, chronic obstructive pulmonary disease (COPD), asthma)
  • Sickle cell disease

Other treatments that might be considered if hospitalized at ANMC and deemed appropriate by your care team:

  • Dexamethasone
  • Tocilizumab
  • Baricitinib

The Infectious Disease team at ANMC is constantly reviewing new clinical trials and reviewing potential treatment options that are safe and approved for the treatment of COVID-19 using guidance from the Infectious Diseases Society of America (IDSA) and National Institutes of Health (NIH). Treatments vary by the stage and severity of an individual’s COVID-19 illness, as well as underlying medical conditions an individual may have.